The efficacy and safety of crizotinib in the treatment of anaplastic lymphoma kinase-positive non-small cell lung cancer: a meta-analysis of clinical trials

BACKGROUND: Crizotinib was granted accelerated approval by the Food and Drug Administration in 2011 for the treatment of anaplastic lymphoma kinase (ALK)-positive non-small cell lung cancer (NSCLC). To evaluate the efficacy and safety of crizotinib, we performed a meta-analysis of published clinical...

Descripción completa

Detalles Bibliográficos
Autores principales: Qian, Haili, Gao, Feng, Wang, Haijuan, Ma, Fei
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2014
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4180325/
https://www.ncbi.nlm.nih.gov/pubmed/25239305
http://dx.doi.org/10.1186/1471-2407-14-683

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4180325/
https://www.ncbi.nlm.nih.gov/pubmed/25239305
http://dx.doi.org/10.1186/1471-2407-14-683

Ejemplares similares